LAVAS Study
Start date:Historic End date:
June 2014 Co-ordinated by:
NHS Lothian
Lactate, Arterial and Venous Agreement in Sepsis – LAVAS trial
Aim
To determine whether an agreement between peripheral venous and arterial lactate exists in patients presenting to an Emergency Department with sepsis.
Trial Design
A prospective observational study in a consecutive sample of eligible and consented patients in the Royal Infirmary of Edinburgh
Eligibility criteria (summary)
Patients who present to the Emergency Department with suspected sepsis
Chief Investigator
Dr Deepankar Datta
Specialist Trainee Emergency Medicine
Local PI
Dr Deepankar Datta
Specialist Trainee Emergency Medicine
Research Team
Julia Grahamslaw
Lead Research Nurse
More EMERGE Trials
The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.
The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.
This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.
Participants will be asked to return for 6 visits across 12 months to evaluate their health.
Across the UK the trial aims to recruit 10,260 volunteers.
If you are interested in taking part, please click on this link and complete the online questionnaire: https://www.covid19vaccinetrial.co.uk/participate-edinburgh
COV_002 Vaccine Trial
The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.
ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study
ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)